
1. A formulation comprising:

(a) at least one active pharmaceutical ingredient wherein the at least one active pharmaceutical ingredient comprises a compound of formula (I)



(I);

(b) at least one solubilizer selected from medium-chain fatty acid triglycerides, polyoxyethylated glycerides, a combination of medium-chain fatty acid mono- and

diglycerides, and combinations thereof;

(c) at least one surfactant which is polyoxyethylene sorbitan monooleate; and

(d) at least one stabilizer which is butylated hydroxytoluene.

2. The formulation of claim 1 wherein the at least one active pharmaceutical ingredient is included in the range from ~~about~~ 1 to ~~about~~ 40% w/w.

3. The formulation of claim 1 wherein the at least one stabilizer is included in the range from ~~about~~ 0.05 to ~~about~~ 0.2% w/w.

4. The formulation of claim 1 wherein the at least one solubilizer is medium-chain fatty acid triglycerides and a combination of medium-chain fatty acid mono- and diglycerides.

5. The formulation of claim 4 wherein the at least one solubilizer is included in the range from ~~about~~ 10 to ~~about~~ 80% w/w.


6. The formulation of claim 5 wherein the at least one surfactant is included in the range from ~~about~~ 15 to ~~about~~ 40% w/w.

7. The formulation of claim 1 wherein the at least one solubilizer is polyoxyethylated glycerides.

8. The formulation of claim 7 wherein the at least one solubilizer is included in the range from ~~about~~ 1 to ~~about~~ 80% w/w.

9. The formulation of claim 7 wherein the at least one surfactant is included in the range from ~~about~~ 1 to ~~about~~ 40% w/w.

~~10. The use of a formulation comprising Compound (I) having the formula:~~



~~(I),~~

~~in the manufacture of a drug orally administered to a fasted or fed mammalian subject to provide a total blood plasma concentration profile of Compound (I), as measured by AUC at 24 hours after an initial dose of the composition, that is at least greater than about 50% of the total blood plasma concentration as measured by AUC at 24 hours of an initial dose of an orally administered solution comprising Compound (I).~~

~~11. The use of claim 10, wherein the AUC is at least greater than about 60% of the AUC at 24 hours of the solution when orally administered regardless if the subject is fasted or fed.~~

~~12. The use of claim 10, wherein the AUC is at least greater than about 70% of the AUC at 24 hours of the solution when orally administered regardless if the subject is fasted or fed.~~


~~13. The use of claim 10, wherein the AUC is at least greater than about 80% of the AUC at 24 hours of the solution when orally administered regardless if the subject is fasted or fed.~~

~~14. The use of claim 10, wherein the AUC is at least greater than about 90% of the AUC at 24 hours of the solution when orally administered regardless if the subject is fasted or fed.~~

~~15. The use of claim 10, wherein the formulation is in a form of a capsule.~~

~~16. The use of claim 10, wherein the formulation is in a form of a solubilized capsule.~~

~~17. The use of a composition comprising Compound (I) having the formula:~~



~~(I),~~

~~in the manufacture of a drug orally administered to a fasted mammalian subject to provide a blood plasma concentration profile after an initial dose of the composition with a Cmax of Compound (I) after an initial dose of the composition that is at least greater than about 40% of the Cmax of an orally administered solution comprising Compound (I).~~

~~18. The use of claim 17, wherein the Cmax of the composition is at least or greater than about 50% of the Cmax of an orally administered solution.~~

~~19. The use of claim17, wherein the Cmax of the composition is at least or greater than about 60% of the Cmax of an orally administered solution.~~

~~20. The use of claim 17, wherein the Tmax is at least about 3 hours.~~

~~21. The use of claim 17, wherein the formulation is in a form of a capsule.~~


~~22. The use of claim 17, wherein the formulation is in a form of a solubilized capsule.~~

~~23. The use of an oral solid dosage composition comprising at least one poorly soluble active pharmaceutical ingredient in the manufacture of a drug orally administered to a fasted mammalian subject to provide a total blood plasma concentration profile as measured by AUC at 24 hours after an initial dose of the composition that is at least greater than about 50% of the total blood plasma concentration as measured by AUC at 24 hours of an initial dose of an orally administered solution comprising the at least one active pharmaceutical ingredient.~~

~~24. The use of claim 23, wherein the active pharmaceutical ingredient exhibits a significant food effect.~~

~~25. The use of claim 23, wherein the at least one active pharmaceutical ingredient is included in the range from about 0.1 to about 60% w/w.~~

~~26. The use of a formulation comprising Compound (I) having the formula~~



~~(I),~~

~~in the manufacture of a drug orally administered to a fasted mammalian subject, and the formulation has a fed to fasted ratio lower than at least about 2.~~

~~27. The use of claim 26, wherein the fed to fasted ratio is less than about 1.5.~~

~~28. The use of claim 26, wherein the fed to fasted ratio is less than about 1.0.~~

~~29. The use of claim 26, wherein the fed to fasted ratio is less than about 0.75.~~

~~30. The use of claim 26, wherein the formulation is in a form of a capsule.~~

~~31. The use of claim 26, wherein the formulation is in a form of a solubilized capsule.~~

32. Use of a therapeutically effective amount of the formulation of claim 1 in the manufacture of a medicament for treating an HCV infection.